Psoriasis combo therapy trial ends early: what happened?
NCT ID NCT02829424
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding low-dose methotrexate to standard anti-TNF therapy could improve and extend the response in adults with moderate to severe psoriasis. The trial planned to enroll 78 participants but was terminated early. The main goal was to see how long patients maintained at least a 75% improvement in their psoriasis symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methotrexate
- What this could lead to
- If it worked, this could show that adding methotrexate helps people with psoriasis maintain a better response to anti-TNF drugs for longer.
- What could go wrong
- The trial was terminated early with only 78 participants, so results are limited. It is a Phase 4 study, meaning the drugs are already approved, so no breakthrough is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique Hôpitaux de Marseille
Marseille, 13385, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis